A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy), Richard Greil(Paracelsus Medical University)
Cited by 18
Related Papers
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
|Journal of Clinical Oncology|2011|190
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
|ESMO Open|2016|129
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
|Journal of Clinical Oncology|2019|111
Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells
|International Journal of Cancer|1995|70